OPCH · Option Care Health, Inc.

Option Care Health's first quarter 2026 results reflected mixed performance, with management acknowledging dissatisfaction with revenue growth momentum. Net revenue rose 1.3% to $1,350.7 million, driven by high single-digit growth in the Acute segment and solid performance in the IG/neuro portfolio. However, these gains were partially offset by a decline in the chronic inflammatory disease (CID) portfolio and certain other specialty therapies within the Chronic segment. GAAP net income declined 3.0% to $45.3 million, while Adjusted EBITDA decreased 6.3% to $104.8 million, reflecting the CID headwind despite strong Acute execution. Adjusted diluted EPS remained flat year-over-year at $0.40, supported by share repurchase activity.

Management updated full-year 2026 guidance to reflect ongoing challenges in the CID portfolio. The company now expects net revenue of $5.675 billion to $5.775 billion, incorporating an approximate 600 basis point headwind from CID. Despite the revenue adjustment, management maintained its Adjusted EBITDA guidance of $480 million to $505 million and Adjusted diluted EPS guidance of $1.82 to $1.92, citing confidence in mitigation efforts and operational execution. The company also maintained its target for cash provided by operating activities of at least $320 million. During the quarter, the company expanded its revolving credit facility from $400 million to $850 million, enhancing liquidity. CEO John C. Rademacher emphasized that the organization is taking decisive actions to re-accelerate growth trajectory and position the company for greater long-term value creation.